What are the real-world outcomes following treatment with teclistamab in RRMM?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Danai Dima, Taussig Cancer Institute, Cleveland, US. We asked, What are the real-world outcomes following treatment with teclistamab in relapsed/refractory multiple myeloma?

Dima provides a summary of data from the MajesTEC-1 trial (NCT03145181), which led to the regulatory approval of teclistamab. She highlights variation in patient demographics between the clinical trial and real-world settings, emphasizing outcomes for those who were ineligible for the trial. She then evaluates data from patients with high-risk features, extramedullary disease, and prior B-cell maturation antigen-targeted therapies. Dima concludes with a discussion on how treatment with teclistamab may be incorporated into the community care setting.